Cargando…

Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies

Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maglione, Alessandro, Morra, Marta, Meroni, Raffaella, Matta, Manuela, Clerico, Marinella, Rolla, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957380/ https://www.ncbi.nlm.nih.gov/pubmed/35364386 http://dx.doi.org/10.1016/j.msard.2022.103776

Ejemplares similares

Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis
por: Maglione, Alessandro, et al.
Publicado: (2023)

Feeding the gut microbiome: impact on multiple sclerosis
por: Bronzini, Matteo, et al.
Publicado: (2023)

Host Genetics and Gut Microbiome: Perspectives for Multiple Sclerosis
por: Maglione, Alessandro, et al.
Publicado: (2021)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View
por: Maglione, Alessandro, et al.
Publicado: (2019)

Computational modeling of the immune response in multiple sclerosis using epimod framework
por: Pernice, Simone, et al.
Publicado: (2020)

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
por: Nishikubo, Masashi, et al.
Publicado: (2023)

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question
por: De Mercanti, Stefania Federica, et al.
Publicado: (2020)

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
por: Rolla, Simona, et al.
Publicado: (2022)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
por: Iannello, Andrea, et al.
Publicado: (2019)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms
por: Ayers, Emily, et al.
Publicado: (2023)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen
por: Uyemura, Bradley S., et al.
Publicado: (2022)

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
por: Wallach, Asya I., et al.
Publicado: (2022)

Besides human booster doses: Could vaccinating highly susceptible animals to SARS-CoV-2 be the needed urgent strategic step?
por: Saied, AbdulRahman A.
Publicado: (2022)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
por: Harrington, Patrick, et al.
Publicado: (2022)

New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster
por: Arismendez, Alan A., et al.
Publicado: (2023)

A three-dose inactivated SARS-CoV-2 vaccine is sufficient to elicit humoral immune responses in people living with HIV-1
por: Yu, Haisheng, et al.
Publicado: (2023)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients
por: Khan, Qamar J., et al.
Publicado: (2022)

Protective humoral immunity in SARS-CoV-2 infected pediatric patients
por: Zhang, Yaguang, et al.
Publicado: (2020)

Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant
por: Zhang, Wei, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod
por: Mallucci, Giulia, et al.
Publicado: (2020)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Implications of COVID-19 vaccine boosters amid the emergence of novel variants of SARS-CoV-2
por: Dhawan, Manish, et al.
Publicado: (2022)

Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine
por: Peng, Pai, et al.
Publicado: (2021)

Bronchial Mucosal Microcirculation in SARS-CoV-2 Infection: Role in Innate Humoral Defense?
por: Persson, Carl
Publicado: (2022)

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2
por: Ukey, Rahul, et al.
Publicado: (2022)

Reply to Comment on: “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease”
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_958u4up6rbkdm5nbf9b2arg6g5